These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36745212)

  • 21. Prophylactic efficacy on periprosthetic bone loss in calcar region after total hip arthroplasty of antiosteoporotic drugs: a network meta-analysis of randomised controlled studies.
    Chen X; Shen Y; Ye C; Mumingjiang Y; Lu J; Yu Y
    Postgrad Med J; 2021 Mar; 97(1145):150-155. PubMed ID: 32114493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Denosumab prevents periprosthetic bone mineral density loss in the tibial metaphysis in total knee arthroplasty.
    Murahashi Y; Teramoto A; Jimbo S; Okada Y; Kamiya T; Imamura R; Takashima H; Watanabe K; Nagoya S; Yamashita T
    Knee; 2020 Mar; 27(2):580-586. PubMed ID: 31928902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis.
    Zhou W; Liu Y; Guo X; Yang H; Xu Y; Geng D
    Osteoporos Int; 2019 Aug; 30(8):1581-1589. PubMed ID: 31115592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Zoledronic acid and denosumab for periprosthetic bone mineral density loss after joint arthroplasty: a systematic review and meta-analysis of randomized controlled trials.
    Li X; Han J; Shi X; Bi Z; Liu J
    Arch Osteoporos; 2023 Feb; 18(1):37. PubMed ID: 36840811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.
    Saag KG; Wagman RB; Geusens P; Adachi JD; Messina OD; Emkey R; Chapurlat R; Wang A; Pannacciulli N; Lems WF
    Lancet Diabetes Endocrinol; 2018 Jun; 6(6):445-454. PubMed ID: 29631782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Periprosthetic bone remodelling of two types of uncemented femoral implant with proximal hydroxyapatite coating: a 3-year follow-up study addressing the influence of prosthesis design and preoperative bone density on periprosthetic bone loss.
    Rahmy AI; Gosens T; Blake GM; Tonino A; Fogelman I
    Osteoporos Int; 2004 Apr; 15(4):281-9. PubMed ID: 14661072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of etidronate in preventing periprosthetic bone loss following cemented hip arthroplasty: a randomized, double blind, controlled trial.
    Fokter SK; Komadina R; Repse-Fokter A
    Wien Klin Wochenschr; 2006; 118 Suppl 2():23-8. PubMed ID: 16817039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Bone Remodelling in the Proximal Femur after Uncemented Total Hip Arthroplasty in Patients with Osteoporosis].
    Lacko M; Schreierová D; Čellár R; Vaško G
    Acta Chir Orthop Traumatol Cech; 2015; 82(6):430-6. PubMed ID: 26787184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of switching administration of alendronate after teriparatide for the prevention of BMD loss around the implant after total hip arthroplasty, 2-year follow-up: a randomized controlled trial.
    Morita A; Kobayashi N; Choe H; Ike H; Tezuka T; Higashihira S; Inaba Y
    J Orthop Surg Res; 2020 Jan; 15(1):17. PubMed ID: 31948455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Denosumab on Femoral Periprosthetic BMD and Early Femoral Stem Subsidence in Postmenopausal Women Undergoing Cementless Total Hip Arthroplasty.
    Aro HT; Nazari-Farsani S; Vuopio M; Löyttyniemi E; Mattila K
    JBMR Plus; 2019 Oct; 3(10):e10217. PubMed ID: 31687650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Female patients with low systemic BMD are prone to bone loss in Gruen zone 7 after cementless total hip arthroplasty.
    Alm JJ; Mäkinen TJ; Lankinen P; Moritz N; Vahlberg T; Aro HT
    Acta Orthop; 2009 Oct; 80(5):531-7. PubMed ID: 19916684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of bisphosphonates in preventing femoral periprosthetic bone resorption after primary cementless total hip arthroplasty: a meta-analysis.
    Zhao X; Hu D; Qin J; Mohanan R; Chen L
    J Orthop Surg Res; 2015 May; 10():65. PubMed ID: 25962791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of risedronate on bone metabolism after total hip arthroplasty: a prospective randomised study.
    Kinov P; Tivchev P; Doukova P; Leithner A
    Acta Orthop Belg; 2006 Jan; 72(1):44-50. PubMed ID: 16570894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of denosumab treatment on the expression of receptor activator of nuclear kappa-B ligand (RANKL) and TNF-receptor TNFRSF9 after total hip arthroplasty-results from a randomized placebo-controlled clinical trial.
    Sköld C; Kultima K; Freyhult E; Larsson A; Gordh T; Hailer NP; Mallmin H
    Osteoporos Int; 2022 Sep; 33(9):1-8. PubMed ID: 35608639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
    Nakamura Y; Suzuki T; Kato H
    Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alendronate prevents femoral periprosthetic bone loss following total hip arthroplasty: prospective randomized double-blind study.
    Arabmotlagh M; Rittmeister M; Hennigs T
    J Orthop Res; 2006 Jul; 24(7):1336-41. PubMed ID: 16705719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study.
    Khan AA; AbuAlrob H; M'Hiri I; Ali DS; Dandurand K; Said H; Alkassem H; Hakami Y; Hweija I; Iqbal S; Romanovschi M; Mehmood S; Zariffeh H; Guyatt G; Ibrahim Q; Brignardello-Petersen R; Syed HI
    Endocrine; 2023 Jun; 80(3):647-657. PubMed ID: 37186270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A long-lasting bisphosphonate partially protects periprosthetic bone, but does not enhance initial stability of uncemented femoral stems: A randomized placebo-controlled trial of women undergoing total hip arthroplasty.
    Aro E; Moritz N; Mattila K; Aro HT
    J Biomech; 2018 Jun; 75():35-45. PubMed ID: 29747966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.
    Mori Y; Kasai H; Ose A; Serada M; Ishiguro M; Shiraki M; Tanigawara Y
    Osteoporos Int; 2018 May; 29(5):1155-1163. PubMed ID: 29423715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.